1Long JL, et al. (2008) Incidence and outcomes of malignancy in the
HAART era in an urban cohort of HIV-infected individuals. AIDS.
22: 489-496.
2D'Souza G, et al. (2014) Epidemiology of head and neck squamous
cell cancer among HIV-infected patients. J Acquir Immune Defic
Syndr 65: 603-610.
3Brickman, C. and J.M. Palefsky (2015) Cancer in the HIV-Infected
Host: Epidemiology and Pathogenesis in the Antiretroviral Era. Curr
HIV/AIDS Rep 12:388-396.
4Pacheco, Y.M., et al. (2015) Increased risk of non-AIDS-related
events in HIV subjects with persistent low CD4 counts despite cART
in the CoRIS cohort. Antiviral Res 117: 69-74.
5Bruyand M, et al. (2009) Role of uncontrolled HIV RNA level and
immunodeficiency in the occurrence of malignancy in HIV-infected
patients during the combination antiretroviral therapy era: Agence
Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort.
Clin Infect Dis 49: 1109-1116.
6Neuhaus J, et al. (2010) Markers of inflammation, coagulation, and
renal function are elevated in adults with HIV infection. J Infect Dis
201: 1788-1795.
7Borges AH, et al. (2013) Predicting risk of cancer during HIV infection:
the role of inflammatory and coagulation biomarkers. AIDS
27:1433-1441.
8Romani BS, Engelbrecht RH (2010) Glashoff, Functions of Tat: the
versatile protein of human immunodeficiency virus type 1. J Gen Virol
91:1-12.
9Kim RH, et al. (2008) HIV-1 Tat enhances replicative potential of
human oral keratinocytes harboring HPV-16 genome. Int J Oncol
334: 777-782.